Mr. Mack is the Company's Current CFO "On behalf of Gain, I would like to thank Matthias for his significant contribution to the development of our company, as we advanced our lead candidate, GT-02287, into clinical development. Matthias played an instrumental role building the preclinical dossier for GT-02287 including the most recent positive data presented this week at FENS Forum 2024, in which administration of GT-02287 was associated with significant improvement in cognitive performance and other relat ...

Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder's departure, the ...

The poster, titled, "GT-02287, a Clinical-Stage GCase Enhancer, Improves Activities of Daily Living and Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease," which will be presented on-site on June 27th by Dr. Beatriz Calvo-Flores Guzman and available online the same day demonstrates how GT-02287 improves nest-building performance and motor performance in a mouse model of GBA1-PD. Nest building in rodents is a natural and spontaneous behavior that closely resembles the tasks of daily li ...

A PDF of the poster presented at the FENS Forum 2024 conference is available on the Science & Technology section of the Company's website at https://www.gaintherapeutics.com/science-and-technology/posters. Forward Looking Statements Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's with GBA, as well "These data further confirm our conviction that GT-02287 can slow or st ...

About Gain Therapeutics, Inc. Leveraging AI-supported structural biology, proprietary algorithms, and supercomputer-powered physics-based models, the company's Magellan™ drug discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Its AI and machine-learning tools and virtual screening capabilities leverage the emerging on-demand compound libraries covering vast chemical spaces of over five ...

BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's Chief Financial Officer, Gene Mack, will participate in a fireside chat and host virtual one-on-one meetings at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference taking place June 27, 2024. Time: 7:00am E ...

Gain Therapeutics (NASDAQ:GANX) stock is falling on Friday following the pricing of its shares in a public offering. Gain Therapeutics is also offering underwriters the option of acquiring another 1,222,222 shares in this public offering. Titan Partners Group is acting as the sole bookrunner for this offering. With this public offering, Gain Therapeutics is increasing the total number of outstanding shares. Doing so dilutes the stakes of current investors in the biotechnology company. That's one reason why ...

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. ("Gain" or the "Company") (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a public offering price of $1.35 per share and (ii) pre-funded warrants to purchase 1,031,602 shares of common stock in lieu of shares of common stock to certain investors. The pre-funded warrants will be immediately exercisable, and may be exercised at any time after their original issu ...

Titan Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the offering. Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson's disease and for general corporate purposes. About Gain Therapeutics, Inc. Gain's unique approach enables the discovery of novel, allosteric small molecule modulators that can resto ...

Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson's disease and for general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The securities de ...